Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
暂无分享,去创建一个
M. Grever | S. Pileri | M. Berger | O. Abdel-Wahab | R. Foà | N. Rosen | A. Saven | B. Falini | Sasinya N. Scott | M. Lacouture | R. Levine | D. Rossi | S. Ascani | P. Zinzani | S. Devlin | K. Rai | M. Tallman | R. Stone | J. Altman | M. Varettoni | Christopher Y. Park | A. Ambrosetti | Eunhee Kim | Y. R. Chung | A. Rambaldi | A. Carella | L. De Carolis | E. Tiacci | A. Pulsoni | P. Leoni | F. Zaja | M. Martelli | A. Broccoli | A. Anastasia | Stephen S. Chung | Jae H. Park | F. Falzetti | M. Cimminiello | M. Capponi | G. Motta | V. Fraticelli | S. Chung | R. Levine
[1] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[2] B. Falini,et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. , 2015, Blood.
[3] M. Berger,et al. Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia , 2014, Science Translational Medicine.
[4] G. Verhoef,et al. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib , 2014, Annals of Hematology.
[5] M. Holderfield,et al. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors , 2014, British Journal of Cancer.
[6] Donavan T. Cheng,et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. , 2014, Cancer discovery.
[7] I. Schmidt-Wolf,et al. Hairy cell leukemia: short review, today's recommendations and outlook , 2014, Blood Cancer Journal.
[8] A. Saven,et al. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. , 2014, Blood.
[9] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[10] V. Sondak,et al. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma , 2013, Nature Reviews Clinical Oncology.
[11] E. Hsi,et al. Phospho-ERKTHR202/Tyr214 Is Overexpressed in Hairy Cell Leukemia and Is a Useful Diagnostic Marker in Bone Marrow Trephine Sections , 2013, The American journal of surgical pathology.
[12] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[13] B. Falini,et al. Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia. , 2012 .
[14] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[15] Patrick T. Walsh,et al. Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice , 2012, PloS one.
[16] P. Hirth,et al. Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.
[17] K. Basso,et al. A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK–JNK pathways , 2012, Leukemia.
[18] C. von Kalle,et al. BRAF inhibition in refractory hairy-cell leukemia. , 2012, The New England journal of medicine.
[19] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[20] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[21] K. Flaherty,et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.
[22] R. Foà,et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.
[23] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[24] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[25] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[26] M. Grever. How I treat hairy cell leukemia. , 2010, Blood.
[27] A. Rohatiner,et al. Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis , 2009, British journal of haematology.
[28] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[29] H. Kantarjian,et al. Eradication of minimal residual disease in hairy cell leukemia. , 2006, Blood.
[30] M. Piris,et al. Evolving concepts in the pathogenesis of hairy-cell leukaemia , 2006, Nature Reviews Cancer.
[31] Katia Basso,et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1) , 2004, The Lancet.
[32] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[33] K. Basso,et al. Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors , 2004, The Journal of experimental medicine.
[34] J. Cawley,et al. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways , 2003, Oncogene.
[35] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[36] C. Dinarello,et al. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. , 1998, European cytokine network.
[37] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[38] Jeffrey W. Clark,et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia , 1988 .
[39] J. Vardiman,et al. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. , 1983, Blood.
[40] M. Grever,et al. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[41] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[42] A. Tefferi,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[43] J. Stockman,et al. Distinct Sets of Genetic Alterations in Melanoma , 2007 .
[44] D. Catovsky,et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. , 1994, Leukemia & lymphoma.
[45] D. Longo,et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. , 1988, Blood.
[46] H. Pralle,et al. [Hairy cell leukemia]. , 1976, Hamatologie und Bluttransfusion.